Five quick points:
1. Under the offering, Aurora Spine issued 5.5 million units at about $0.19 each, for aggregate gross proceeds of roughly $1.04 million.
2. Proceeds from the private placement financing will be used for “general corporate purposes,” according to a Feb. 3 press release.
3. Each whole warrant will be exercisable at about $0.34 per common share for three years after the issue date.
4. Securities issued are subject to a four-month hold period, and the offering is pending final TSX Venture Exchange approval.
5. Aurora Spine expects to complete at least one more additional tranche on the same terms.
More articles on devices:
‘The most expensive drug in the world’ — 10 details on Novartis’ $2.1M drug for spinal muscular atrophy
Zimmer Biomet 2019 sales hit $8 billion: 7 things to know
8 orthopedic practices partnering with hospitals, health systems
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.